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Background: Brain arteriovenous malformation (BAVM) is a rare pathology diagnosed mostly
in young adults. However, due to its hemorrhagic complications, it constitutes an important
clinical problem. Treatment modalities available include endovascular, surgery and radiosurgery.
The aim of the study was to assess the efﬁcacy and safety of endovascular treatment of
BAVM with Onyx® by reporting one-center experience.
Material and methods: Between 2006 and 2013, 54 patients with BAVM were embolized with
Onyx. The group consisted of 24 males and 30 females, aged 10 to 65 years (mean 42.6  15.4).
Clinical manifestations of BAVMs were: hemorrhage in 27 (50.0%), headaches in 12 (22.2%),
seizures in 7 (13.0%) and focal neurologic deﬁcits in 2 (3.7%) patients. Six (11.1%) patients
were asymptomatic. A majority of BAVMs were of II and III grade in Spetzler-Martin scale (19
and 22 cases respectively).
Results: A total number of 108 endovascular procedures were performed (mean 2.00  0.98
sessions/patient). Complete obliteration of malformation was achieved in 25 (46.3%) patients,
mostly with grade II and III BAVMs. In 29 (53.7%) patients, embolization led to a decrease in size
of BAVM that made it feasible for other treatment modality. Morbidity and mortality rates were
5.6% and 1.8% respectively. The rate of hemorrhagic complications was 9.3%.
Conclusion: Embolization of BAVM with Onyx® is an effective and safe method of treatment.
However, regarding type and consequences of complications, the technique needs further
improvement.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Endovascular treatment is one of the modalities, alongside
neurosurgical excision and radiosurgery, which is nowadays
available for the management of brain arteriovenous mal-
formations (BAVM). The ﬁrst liquid embolic agent introduced
to the treatment of BAVM was n-butyl cyanoacrylate (n-BCA).
However, due to its fast polymerization after contact with
ionic substances in blood and poor intraoperative control,
n-BCA enables complete occlusion of BAVM in very limited
number of patients, even if used by an experienced
neurointerventionist [1,2]. Onyx (Covidien ev3, Irvine, CA,
USA) is polymer of ethyl vinyl alcohol dissolved in dimethyl
sulfoxide (DMSO), which precipitates and thus allows slower
injection with better control and penetration to the nidus of
BAVM. It seems to be more promising and safer for both
patients and neurointerventionist [3,4]. Onyx was approved
in Europe in 1999 and became a commonly used embolic
agent in everyday endovascular practice around 2004/2005
[5]. Since then, the indications for use of n-BCA were reduced
and accessibility of endovascular treatment of BAVM was
facilitated. This method of treatment became available
beyond selected experienced centers. Although, a complex-
ity of the pathology and its low incidence still requires the
highest level of expertise from a medical team dealing with
this problem.
The aim of the report was to deﬁne the efﬁcacy of
endovascular treatment of BAVM with Onyx with particular
emphasis on its safety and complete cure rate by reporting
single-center experience with this method.
2. Material and methods
2.1. Patient's selection
The Onyx liquid embolic agent has European Conformity
Marking (CE Mark) and is routinely utilized in our institution.
Application of Onyx did not require ethical committee
approval for this observational study. The study was
performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later
amendments. Informed consent was obtained from all
patients.
The studied population included patients with the diagno-
sis of BAVM conﬁrmed by preoperative digital subtraction
angiography (DSA) who underwent endovascular treatment
using Onyx in one interventional neuroradiological center
from 2006 to 2013. All patients were qualiﬁed for endovascular
therapy by a multidisciplinary team of physicians experienced
in BAVM treatment, representing at least three medical
specialties: neurosurgery, interventional neuroradiology and
anesthesiology. In the center included in this report, emboli-
zation was established as the ﬁrst line treatment of mal-
formations with an intention to cure. All of the patients with a
non-hemorrhagic manifestation of BAVM have been treated
before publication of ARUBA trial (A Randomized Trial of
Unruptured Brain Arteriovenous Malformations) partial
results in November 2013 [6].2.2. Endovascular procedure
Endovascular treatment in all patients was performed with
intention to cure that is to completely occlude BAVM.
Neuroradiologist with over 10-years experience in endovas-
cular neurointerventions performed all embolizations. Onyx
was used as a sole embolic agent in all cases and its injection
was determined by the possibility of distal access to the nidus
and anatomy of BAVM.
Each procedure was performed under general anesthesia,
through femoral access using Avanti 6F sheath introducer
(Cordis, Bridgewater, NJ, USA) and was preceded by intrave-
nous bolus of 2000 IU of heparin in a case of unruptured BAVM.
Guiding catheter Envoy 6F (Cordis, Bridgewater, NJ, USA) or
Guider Soft (Boston Scientiﬁc, Fremont, CA, USA) was then
placed under ﬂuoroscopy in either internal carotid or vertebral
artery being main supply to the malformation. Subsequently,
DMSO compatible microcatheter Sonic (Balt Extrusion, Mont-
morency, France) with detachable tip, or undetachable
microcatheter Marathon (Covidien ev3, Irvine, CA, USA) was
introduced into the feeding artery over guidewire SilverSpeed
(Covidien ev3, Irvine, CA, USA), Traxcess (Microvention
Terumo, Tustin, CA, USA) or Hybrid (Balt Extrusion, Montmo-
rency, France). A proper working position of microcatheter was
conﬁrmed by monoplane microangiography. Microcatheter
was then ﬂushed with recommended volume of DMSO and
its dead space ﬁlled with Onyx, which was injected slowly
under continuous control of monoplane subtraction ﬂuo-
roscopy with 30–120 s breaks for building reﬂux over the tip
of microcatheter in the feeding pedicle. The injection was
stopped and microcatheter removed when control angiog-
raphy showed a total occlusion of the whole nidus or its
intended part or the length of reﬂux was considered critical
(15 mm). Control 3-vessel DSA completed each procedure. If
no complications occurred, a patient was woken up from
general anesthesia and observed ﬁrst in ICU, then in
neurosurgery ward for at least 24 h with continuous
monitoring of BP.
2.3. Data collection
For all patients, age and gender were noted. The following
data describing the clinical presentation were recorded:
intracranial hemorrhage, headaches, seizures and neuro-
logical deﬁcits. The following data regarding BAVM were
analyzed: localization categorized as the cerebral hemi-
sphere, cerebellum, basal ganglia incl. thalamus and corpus
callosum; nidus size divided into categories: <3 cm, 3–6 cm
and >6 cm; outﬂow type categorized as superﬁcial or deep;
number of outﬂows and feeding arteries as single or
multiple; additional anatomical risk factors, such as aneu-
rysm of the feeding artery, ectasia, stenosis of the draining
vein and ﬁstula. All lesions were categorized according to
the Spetzler-Martin grading scale. A number of embolization
sessions was noted.
The angiographic result was categorized as complete
(100%) or incomplete (<100%) obliteration of BAVM, based
on post-procedural DSA. Initial and ﬁnal DSA was assessed by
the neuroradiologist performing embolization. Procedural
complications of embolization were noted during one-month
Table 1 – Characteristics of the patients and BAVMs.
Characteristics No. (n = 54) and percentage
Symptoms
Hemorrhage 27 (50.0)
Neurological deﬁcits 2 (3.7)
Seizures 7 (13.0)
Headaches 12 (22.2)
Incidental 6 (11.1)
Location
Hemisphere 27 (50.0)
Basal ganglia incl. thalamus 12 (22.2)
Corpus callosum 3 (5.6)
Cerebellum 12 (22.2)
Size
<3 cm 28 (51.9)
3–6 cm 25 (46.3)
>6 cm 1 (1.8)
Outﬂow type
Deep 40 (74.1)
Superﬁcial 14 (25.9)
Number of outﬂows
Single 22 (40.7)
Multiple 32 (50.3)
Number of feeding arteries
Single 28 (51.9)
Multiple 26 (48.1)
Additional features
No additional features 24 (44.4)
Associated aneurysm 7 (13.0)
Fistula 11 (20.4)
Ectasia of the draining vein 8 (14.8)
Stenosis of the draining vein 4 (7.4)
Spetzler-Martin grade
I 5 (9.3)
II 19 (35.2)
III 22 (40.7)
IV 7 (13.0)
V 1 (1.8)
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plete obliteration, information about complementary surgery
and/or radiosurgery was collected. As the aim of the study was
to assess the efﬁcacy and safety of Onyx embolization, the
techniques and results of complementary treatment were not
analyzed.
2.4. Statistical analysis
Age, Spetzler-Martin grading, and number of embolization
sessions were considered continuous variables, with gender,
initial signs and symptoms, localization of BAVM, nidus size,
outﬂow type, number of outﬂows, number of feeding arteries
and additional anatomical risk factors as categorical vari-
ables. The Mann–Whitney U test was used to compare
continuous variables because the distributions of most of
them were signiﬁcantly different from the normal distribu-
tion ( p < 0.05, Shapiro–Wilk test). The chi-squared test (x2)
was used for categorical variables. A multivariate logistic
regression model was used to ﬁnd independent demograph-
ic and clinical predictors of negative treatment outcome.
p < 0.05 was considered statistically signiﬁcant. Statistica
12 software (StatSoft Inc., Tulsa, OK, USA) was used for the
statistical analysis. A medical statistician evaluated the
tests.
3. Results
3.1. Patient's and BAVM's population
The studied population consisted of 54 patients (30 females) at
a mean age of 42.6  15.4 years (range 10–65 years). Char-
acteristics of the patients and BAVMs features are presented in
Table 1.
3.2. Results of endovascular treatment
The aim of embolization that is complete obliteration of the
lesion was achieved in 25 (46.3%) patients. Among 29 patients
with incomplete occlusion, over 75% of BAVM was obliterated
in 13 (44.8%) patients. Detailed results of embolization are
presented in Table 2. Up to 4 sessions were performed in a
single patient with a total number of 108 sessions (mean 2.00
 0.98 sessions/patient) (Fig. 1).
Undetachable catheters were used in 62 (57.4%) sessions,
catheters with detachable tip in 46 (42.6%) sessions.
Two causes of a failure to achieve complete occlusion were
identiﬁed. In some cases, it was impossible to place the
catheter in a proper working position close enough to nidus.
The other cause was an unacceptably long reﬂux, which
occurred before the lesion was completely occluded.
Univariate statistical analysis showed, that risk factors for
failure of complete occlusion were presence of multiple
feeding arteries, nidus size ≥ 3 cm and Spetzler-Martin grade
III–V – see Table 2.
Analysis of multivariate logistic regression revealed, that
the only independent predictor of the failure to achieve
complete occlusion was the presence of multiple feeding
arteries (OR 4.00; 95%CI 1.04–16.64; p = 0.04).3.3. Procedural complications
Complications occurred in 6 out of 108 procedures (5.6% per
procedure). One of them was ischemic and 5 hemorrhagic,
including 4 intracerebral hematomas and 1 subarachnoid
hemorrhage. A detailed description of complications is
presented in Table 3.
Among these 6, we noted one ischemic and one hemor-
rhagic complication related to catheters. In both cases
undetachable microcatheters were used. The difference in
complication rate between undetachable and detachable
catheter group was statistically insigniﬁcant ( p > 0.5; chi-
squared test). However this result could be biased by small
number of complications.
In the ﬁrst case ischemic stroke occurred in Spetzler-Martin
II plexiform BAVM with stenotic draining veins. In this case
undetachable microcatheter was trapped in the single feeder
(PCA) and ruptured during forceful retrieval. Motor and
neuropsychological rehabilitation resulted in partial regres-
sion of symptoms.
The second case was a fatal complication. In this patient,
SAH resulted from tearing of feeding pedicle during retrieval of
trapped undetachable microcatheter. In the following days,
Table 2 – Results of BAVM embolization.
Characteristics Total Complete occlusion Incomplete occlusion p value
Presentation
Hemorrhagic 27 12 (44%) 15 (56%) 0.57
Non-hemorrhagic 27 13 (48%) 14 (52%)
Location
Hemisphere 27 13 (48%) 14 (52%) 0.21
Basal ganglia incl. thalamus 12 4 (33%) 8 (67%)
Corpus callosum 3 1 (33%) 2 (67%)
Cerebellum 12 7 (58%) 5 (42%)
Nidus size
<3 cm 28 21 (75%) 7 (25%) <0.001
≥3 cm 26 4 (15%) 22 (85%)
Outﬂow type
Deep 40 17 (43%) 23 (57%) 0.39
Superﬁcial 14 8 (57%) 6 (43%)
Number of outﬂows
Single 22 10 (45%) 12 (55%) 0.12
Multiple 32 15 (47%) 17 (53%)
Number of feeding arteries
Single 28 21 (75%) 7 (25%) <0.001
Multiple 26 4 (15%) 22 (85%)
Additional features of BAVM
No additional features 24 12 (50%) 12 (50%) 0.19
Associated aneurysm 7 3 (43%) 4 (57%)
Fistula 11 4 (36%) 7 (64%)
Ectasia of the draining vein 8 4 (50%) 4 (50%)
Stenosis of the draining vein 4 2 (50%) 2 (50%)
Spetzler-Martin grade
I–II 24 19 (79%) 5 (21%) 0.004
III–V 30 6 (20%) 24 (80%)
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patient died.
In the remaining 4 cases with intracerebral bleedings
venous congestion was observed before the nidus was
completely occluded. The complications resulted in perma-
nent deﬁcits in two patients while on the other two the
symptoms resolved completely.
This gave procedure-related hemorrhagic complications
rate of 9.3%, morbidity of 5.6% and mortality of 1.8%.
3.4. Complementary treatment
Complementary treatment was performed in 8 patients with
incomplete occlusion of BAVM: 7 of them received radiosur-
gery and one patient underwent surgery. Additionally, 4
patients refused complementary treatment. As the aim of the
study was to assess the efﬁcacy and safety of Onyx emboliza-
tion, the technique and results of complementary treatment
were not analyzed.
4. Discussion
BAVMs constitute a group of complex and rare pathological
vascular shunts. Their incidence is estimated at approximate-
ly 1 per 100,000 per year and they are usually diagnosed in
patients between 30 and 40 years affecting both genders at the
same percentage [7–11]. The cumulative risk of BAVM bleeding
is 2–4%, increasing to 6% in the ﬁrst year after the ﬁrst
hemorrhagic episode. A major risk and clinical consequence ofBAVM is the possibility of its rupture resulting in intracranial
bleeding. Less severe symptoms include headaches, seizures,
vertigo, tinnitus and, occasionally, focal neurological deﬁcits
(not caused by bleeding but by the malformation itself)
[7,12,13]. BAVM may also remain silent for long periods or
may never manifest any clinical symptoms [9,14]. It is well
known and accepted, that patients presenting with hemor-
rhage have to be treated. The biggest clinical and decision—
making dilemma remains, whether to treat or not to treat the
patients with unruptured BAVMs as soon as we are not able to
predict the clinical course of malformations and distinguish
between patients more susceptible for hemorrhage and those
with minor risk of complications. The bleeding risk of
untreated BAVM is estimated as 2–3% per year [15–18] with
mortality of 10–30% and approximately 20% of permanent
signiﬁcant morbidity [19–22]. The decision making process has
become even more difﬁcult after recently published ARUBA
trial partial results, which showed that the risk of death or
stroke was signiﬁcantly lower in the medical management
group than in the interventional therapy group (hazard ratio
0.27, 95% CI 0.14–0.54) [6]. Considering a short observation time
in the study (mean follow-up 33.3 months) and controversies
in designing it, there are still neither algorithms nor guidelines
for BAVM treatment.
The primary goal of the treatment of brain AVMs is to
prevent bleeding and for this purpose, complete occlusion of
the AVM has to be obtained. Various techniques are available
to treat brain AVMs (surgery, radiosurgery and embolization)
and a combination of techniques is often necessary to obtain a
complete cure of the AVM. Embolization is often the ﬁrst step
Fig. 1 – The case of 37 y/o woman with unruptured BAVM in the left frontal lobe presenting partial seizures, numbness and
altered personality manifesting as severe anger toward her family. Left internal carotid artery injection: a and b –
anteroposterior and lateral view of grade II BAVM; c and d – anteroposterior and lateral view after Onyx embolization.
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reduce the size of the nidus for subsequent treatment (surgery
or radiosurgery). For embolization n-BCA or Onyx are used.
Using n-BCA, prolonged injections are not possible, and only a
limited volume of the nidus can usually be occluded by in a
single injection [4]. In contrast to n-BCA, Onyx is a nonadhesive
liquid. This basic characteristic eliminates the risk of gluing
the catheter to the vessel wall and therefore allows a longer
injection time and a wider range of different injection rates.
Both facilitate occluding larger nidus portions per injection
[23].
The purpose of this retrospective study was to describe
experience our group has made in using Onyx and to compare
our results and complications with those in the literature. Our
results show that this treatment is associated with acceptable
mortality (1.8%), morbidity (5.6%) and hemorrhagic complica-
tions rate (9.3%) with a complete occlusion rate in 46.3% of
patients. These results are quite similar to those reported in
the previous series of patients with brain AVMs treated with
Onyx (Table 4).Particularly, the mortality rate is similar to that reported in
the previous series (0.0–4.3%) [1,5,24–32]. Morbidity is more
heterogeneous from one series to another and ranged from 3.5
to 15.5% [1,5,24–32]. However in more recent series, morbidity
was between 3.5 and 5.1% [30–32]. Finally, our cohort conﬁrms
the results of previous single- and multicentre studies that
show a hemorrhagic complications rate between 4.0 and 12.2%
[29–32].
There were no deaths among non-bleeding patients and
one patient died of procedure—related complications in the
bleeding group. Most of the complications were hemorrhagic
(83%), which corresponds to the results of other authors
[1,24,26–32]. The causes of hemorrhagic complications in our
series included rupture of feeding pedicle during retrieval of
trapped microcatheter (in 1 patient) or hemodynamic changes
in the nidus caused by passage of embolic agent to the venous
side of malformation (in 4 patients). Mounayer et al. and
Maimon et al. [1,33] reported the same complications in their
series. We noted two catheter related complications; associat-
ed with retrieval of trapped undetachable catheter in both
Table 3 – Complications of endovascular treatment.
S-M grade AVM location AVM characteristics Catheter used Complication Clinical
presentation
Treatment Outcome
II Cerebellar Nidus 2.5 cm, plexiform,
1 feeder (right PCA),
multiple draining veins
superﬁcial and deep
with stenosis
Undetachable Ischemic stroke due to
rupture of trapped
microcatheter during
retrieval
Ataxia, vertigo,
partially resolved
after rehabilitation
Conservative Permanent moderate
disability
II Cerebellar Nidus 2 cm, plexiform, 2
feeders, 1 deep draining
vein with stenosis
Detachable Small ICH in 2nd session
probably due to venous
stagnation; AVM
completely occluded in 3
sessions
Transient diplopia,
unilateral deafness
Conservative Permanent unilateral
deafness probably not
related to embolization
V Left fronto-parietal Nidus 6.5 cm, ﬁstulous,
3 feeders, 7 draining
veins (3 deep, 4
superﬁcial)
Undetachable ICH in 4th session due to
venous stagnation; 60%
occlusion was achieved
Disturbance of
consciousness,
psychomotor
hyperactivity, right
sided hemiparesis
Conservative Permanent disability (GOS 4)
IV Left temporo-parietal Nidus 4 cm, ﬁstulous, 3
feeders, 5 deep draining
veins
Undetachable ICH in 2nd session due to
venous stagnation; 70%
occlusion was achieved
Right sided
hemiparesis
Craniectomy and
hematoma evacuation
Transitory disability (GOS 3)
III Left temporo-parietal Nidus 2 cm, plexiform, 1
feeder (left MCA), 3
draining veins (1 deep, 2
superﬁcial)
Detachable ICH with intraventricular
bleeding after complete
occlusion in 1 session,
probably due to venous
stagnation
Right sided
hemiparesis
EVD Transitory disability (GOS 3)
III Cerebellar Nidus 3 cm, plexiform, 1
feeder (right PICA), 1
deep draining vein
Undetachable SAH due to tearing of
feeding pedicle during
retrieval of trapped
microcatheter
Refractory cerebral
edema
Decompressive
craniectomy
Death
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Table 4 – Clinical and anatomical results of the endovascular treatment of BAVMs using Onyx.
Study author and year No. Hemorrhagic complications Morbidity Mortality Complete occlusion
Perez-Higueras, 2005 [24] 45 8.9% 15.5% 2.0% 22.2%
Song, 2005 [25] 50 6.0% 10.0% 0.0% 20.0%
Van Rooij, 2007 [26] 44 6.8% 4.6% 2.3% 16.0%
Weber, 2007 [5] 93 – 12.0% 0.0% 20.0%
Mounayer, 2007 [1] 94 8.5% 8.5% 3.2% 49.0%
Katsaridis, 2008 [27] 101 5.9% 8.0% 3.0% 53.9%
Pierot, 2009 [28] 50 8.0% 8.0% 2.0% 8.3%
Panagiotopoulos, 2009 [29] 82 12.2% 3.8% 2.4% 24.4%
Xu, 2011 [30] 86 7.0% 3.5% 1.2% 18.6%
Saatci, 2011 [31] 350 4.0% 4.3% 1.1% 50.9%
Pierot (BRAVO study), 2013 [32] 127 8.5% 5.1% 4.3% 23.5%
Present series 54 9.3% 5.6% 1.8% 46.3%
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although these available on the market are little less navigable
in comparison to undetachable ones. A major consideration
during endovascular treatment remains still a control of
hemodynamic changes within the nidus and the venous side
of malformation, that was the cause of bleeding in 4 cases in
this study.
It is difﬁcult to compare the rate of complete occlusion from
one series to another because two different strategies in
embolization are used. For some groups, embolization is used
and optimized in order to provide the higher possible rate of
complete occlusion with embolization alone and to appropri-
ately prepare the incompletely embolized AVMs for further
treatment (surgery or radiosurgery). For other groups, emboli-
zation is used as a ﬁrst step treatment to prepare for a second
step (surgery or radiosurgery). Results are heterogeneous from
one series to another (8.3–53.9%) [1,5,24–32]. In the present
study, complete occlusion of BAVM by embolization alone was
achieved in 46.3% of cases, which is similar to the results
reported in the literature from the centers where endovascular
treatment has the intention to cure.
We identiﬁed two causes of a failure to achieve complete
occlusion. The ﬁrst one was an inability to catheterize some
small and tortuous feeders close enough to the nidus. One of
the possible solutions in endovascular treatment of BAVMs
with difﬁcult arterial access could be a transvenous approach
described by Pereira et al. in 2013 [34]. However, the application
of this new technique is limited to small lesions (<3 cm) with a
single, not greatly dilated draining vein. Besides, improve-
ments in designing more maneuverable microcatheters are
needed as well.
The second cause of the failure in the present cohort was
unacceptably long reﬂux which occurred before the sufﬁcient
tidal penetration of Onyx was achieved. This could be avoided
by the usage of pressure cooker technique introduced by
Chapot et al. in 2014 [35]. This technique creates an anti-reﬂux
plug by trapping the detachable part of an Onyx-compatible
microcatheter with coils and glue in order to obtain wedge-
ﬂow conditions and controlled Onyx embolization. The other
possible solution is double—catheterization technique de-
scribed by Abud et al. in 2011 [36] which in selected cases of
small BAVMs, provides better control on the inﬂow to the
malformation and, thus, on the efferents, making emboliza-
tion more predictable.An important role of these two factors is supported by the
results of statistical analysis of predictors for the complete
occlusion failure. In the present study, the factors predicting
the failure included nidus size above 3 cm, S-M grade III-V
and multiple feeders. However, the only independent
predictor of incomplete occlusion was the presence of
multiple feeding arteries. This could be explained by the
fact that multiple feeders are usually found in large BAVMs
with high S-M grade. The difﬁculty of the treatment of large,
high grade BAVMs with multiple feeders was reported in
previous studies [1,33]. In such BAVMs it is more difﬁcult to
achieve complete occlusion due to competitive ﬂow from the
remaining feeding arteries. Despite developing new techni-
ques, endovascular treatment of BAVMs grade III-V still
remains challenging.
5. Conclusions
Endovascular embolization of BAVM using Onyx is an effective
method of treatment. The risk of complications is acceptable
in cases of ruptured BAVMs, but the technique has to be
developed to achieve lower complication rate and decrease
morbidity among patients, who are asymptomatic or present
symptoms other than hemorrhage.
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